Patient characteristics
Fifty-one adult patients (median [range] age of 67 [22–82] years) were enrolled in the study. Among enrolled patients, 27 (52.9%) had received 1 prior induction regimen; 11 (21.6%), 8 (15.7%), and 4 (7.8%) had received 2, 3, or > 3 prior induction regimens, respectively (see Supplementary Table 1 in the Online Resource). Five (9.8%) patients had received ≥ 1 allogeneic HSCT prior to GO treatment. There were 19 (37.3%) patients classified as adverse-risk according to the ELN 2017 recommendations [